CN102090453A - 瘦身美奶茶 - Google Patents
瘦身美奶茶 Download PDFInfo
- Publication number
- CN102090453A CN102090453A CN2011100492163A CN201110049216A CN102090453A CN 102090453 A CN102090453 A CN 102090453A CN 2011100492163 A CN2011100492163 A CN 2011100492163A CN 201110049216 A CN201110049216 A CN 201110049216A CN 102090453 A CN102090453 A CN 102090453A
- Authority
- CN
- China
- Prior art keywords
- fat
- reducing
- acid
- milk
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 32
- 239000008267 milk Substances 0.000 title claims abstract description 32
- 210000004080 milk Anatomy 0.000 title claims abstract description 32
- 241001122767 Theaceae Species 0.000 title description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 66
- 244000269722 Thea sinensis Species 0.000 claims abstract description 62
- 235000009569 green tea Nutrition 0.000 claims abstract description 41
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 37
- 235000013616 tea Nutrition 0.000 claims abstract description 29
- 229920001202 Inulin Polymers 0.000 claims abstract description 26
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 26
- 229940029339 inulin Drugs 0.000 claims abstract description 26
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 20
- 239000000463 material Substances 0.000 claims abstract description 14
- 229940088594 vitamin Drugs 0.000 claims abstract description 13
- 229930003231 vitamin Natural products 0.000 claims abstract description 13
- 235000013343 vitamin Nutrition 0.000 claims abstract description 13
- 239000011782 vitamin Substances 0.000 claims abstract description 13
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 16
- 239000011575 calcium Substances 0.000 claims description 16
- 229910052791 calcium Inorganic materials 0.000 claims description 16
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 5
- 235000019197 fats Nutrition 0.000 abstract description 55
- 229960002663 thioctic acid Drugs 0.000 abstract description 33
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 26
- 230000006870 function Effects 0.000 abstract description 18
- 230000036039 immunity Effects 0.000 abstract description 17
- UZWMCCLZMHPPKW-UHFFFAOYSA-L calcium;2-oxopropanoate Chemical compound [Ca+2].CC(=O)C([O-])=O.CC(=O)C([O-])=O UZWMCCLZMHPPKW-UHFFFAOYSA-L 0.000 abstract description 13
- 230000036772 blood pressure Effects 0.000 abstract description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract description 5
- 235000013376 functional food Nutrition 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 2
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 abstract 2
- 229940108924 conjugated linoleic acid Drugs 0.000 abstract 2
- 229940018333 calcium pyruvate Drugs 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 56
- 239000003925 fat Substances 0.000 description 55
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 33
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 26
- 210000003491 skin Anatomy 0.000 description 24
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 16
- 108090001061 Insulin Proteins 0.000 description 16
- 229940125396 insulin Drugs 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 235000001465 calcium Nutrition 0.000 description 15
- 229960004203 carnitine Drugs 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 230000001093 anti-cancer Effects 0.000 description 14
- 235000013305 food Nutrition 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 235000013365 dairy product Nutrition 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- -1 Cobastab 2 Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 11
- 210000001789 adipocyte Anatomy 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 238000002485 combustion reaction Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000002218 hypoglycaemic effect Effects 0.000 description 10
- 230000004060 metabolic process Effects 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 230000001077 hypotensive effect Effects 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- 150000008442 polyphenolic compounds Chemical class 0.000 description 9
- 235000013824 polyphenols Nutrition 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 208000001953 Hypotension Diseases 0.000 description 8
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 8
- 230000003796 beauty Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 208000021822 hypotensive Diseases 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 206010033307 Overweight Diseases 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 6
- 235000005487 catechin Nutrition 0.000 description 6
- 229950001002 cianidanol Drugs 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 201000005202 lung cancer Diseases 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 230000035790 physiological processes and functions Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 5
- 125000001931 aliphatic group Chemical group 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000013325 dietary fiber Nutrition 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000004407 Lactalbumin Human genes 0.000 description 4
- 108090000942 Lactalbumin Proteins 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 229960001009 acetylcarnitine Drugs 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 229940107700 pyruvic acid Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000003183 carcinogenic agent Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000001055 magnesium Nutrition 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 229960000278 theophylline Drugs 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 235000008939 whole milk Nutrition 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229910001431 copper ion Inorganic materials 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000005213 imbibition Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940049918 linoleate Drugs 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 108010048734 sclerotin Proteins 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019332 Heat exhaustion Diseases 0.000 description 1
- 240000008892 Helianthus tuberosus Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010051467 Nephrectasia Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100021079 Ornithine decarboxylase Human genes 0.000 description 1
- 108700005126 Ornithine decarboxylases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000037208 balanced nutrition Effects 0.000 description 1
- 235000019046 balanced nutrition Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035603 choleresis Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 231100000003 human carcinogen Toxicity 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002832 nitroso derivatives Chemical class 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 231100001223 noncarcinogenic Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于功能食品,尤以牛奶、绿茶、共轭亚油酸、L-肉碱、α-硫辛酸、维生素、菊粉、辅料制成的瘦身美奶茶,该产品的制作工艺:调配混合、搅拌、检验、包装成为正式产品,本产品含有牛奶、绿茶、共轭亚油酸、丙酮酸钙、L-肉碱、α-硫辛酸、维生素、菊粉、辅料,具提高免疫力、减肥、降血压、降血脂、降血糖、美容等功能。
Description
一、技术领域:本发明属功能食品,尤以天然食物为原料,牛奶、绿茶、共轭亚油酸、丙酮酸钙、L-肉碱、α-硫辛酸、维生素、菊粉等原料,采取先进工艺加工而成的功能食品。
二、背景技术:本发明以牛奶、绿茶、丙酮酸钙、L-肉碱、α-硫辛酸、维生素、菊粉等原料制成的功能食品。该产品具有提高免疫力、减肥、降血压、降血脂、降血糖、美容等功能。目前市场上还没有同类产品出现,研制该产品可为给肥胖者提供一种减肥新产品。
三、发明内容:肥胖是一种营养代谢综合失调性疾病和低度全身慢性炎症。研究发现,肥胖病因相当复杂,不仅有明显的遗传性,还与饮食和运动密切相关。在今天肥胖已成为一个社会严重的共公卫生问题。
世界卫生组织(WHO)认为,肥胖与艾滋病、吸毒、凶酒并列为世界四大社会问题,医学界称之为人类死亡率高的癌症,冠心病、糖尿病、高血压、高血脂、心脑血管疾病都与肥胖直接有关。
随着我国经济的快速发展,人民生活水平的不断提高,肥胖正在成为一个关注的流行病。根据世界卫生组织的统计数学显示,全球超重人数超过10亿多,有3亿多人严重肥胖,而发展中国家的肥胖比例大幅增加。在我国根据卫生部、科技部和国家统计局公布的营养与健康状况调查结果显示,我国13亿人口中有2亿人超重,特别是儿童超重迅速增长。预计今后肥胖患病率还将会有较大幅度的增长,肥胖会给国民健康造成严重的威胁,也会给个人和社会带来沉重的经济负担。
四、原料配方:牛奶50千克,绿茶10千克,共轭亚油酸5-7.5千克,丙酮酸钙4-6千克,L-肉碱6-8千克,α-硫辛酸1-2千克,维生素1-2.5克,菊粉1-2.5千克,辅料。
五、技术方案:
(一)牛奶:又称牛乳,性平、味甘、归肺、胃。有补虚、益肺胃、生津润肠。适用于少年、儿童、老年身体虚弱,消化不良,肠燥便秘。现代研究具有促进生长发育、防治骨质疏松、增强免疫力、延缓衰老、降血压、降血糖、减肥、美容、抗癌等功效。
牛奶含有100多种营养成分,蛋白质、氨基酸、碳水化合物、多种维生素、矿物质和微量元素,其中8种人体必需氨基酸比例适宜,特别适合儿童青少年生长发育,增强体质和免疫功能等。
营养功能:1、降血压,近年来研究数据表明,乳制品可能与控制血压相关联。分析证实乳制品的钙比非乳制品钙增补剂降压效果高1倍。研究推测,这可能是由乳制品的钾、镁和钙恰当平衡有利于降血压。乳制品的另一个降血压因素可能使降压生物活性肽。牛奶中的酪蛋白和乳清蛋白都是血管紧张素转换酶(ACE)抑制肽的来源,他们可以通过酶水解、胃肠道消化或食品加过程释放出来。目前,从多种奶酪乳清、酪蛋白、乳清蛋白、β-乳球蛋白等均能分离出抗高血压活性肽,在以自发性高血压大鼠为材料实验中具有降血压活性。
2、降血糖:研究表明,每天喝一些牛奶可降40%的几率患糖尿病。因为牛奶中的钙、镁、维生素D可以增强人体合理使用胰岛素的功能。
另据报道,美国最新研究发现,经常进食全脂奶食品,其中含有一种脂肪酸可降低患2型糖尿病的风险。研究动物实验发现,动物体内存在的棕榈酸可帮助降低胰岛素抵抗性,他们对人体通过奶制品摄入反式棕榈酸进行了调查,研究了3700多名65岁以上老年人进行了跟踪调查。结果显示,与进食奶制品最少的人相比,进食全脂奶制品最多的人患2型糖尿病的几率要低63%。其作用是因为常食全脂奶制品的人血液中的反式棕榈酸的水平较高,同样可以起到降低胰岛素抵抗作用,从而有效预防糖尿病。
3、减肥:近年来多项研究表明,在摄入热量不变的前提下,饮食中增加乳制品的摄入量有助于减肥。因为乳制品含有丰富的钙和其他一些特殊的活性成分,能帮助人体燃烧脂肪,减少脂肪积累和控制体重有着重要的作用。乳制品有助于控制体重的另一个因素可能与它对食欲的控制有关。研究表明,无论在高脂肪或低脂肪膳食条件下,膳食加入乳制品都增加餐后缩胆囊肽的分泌,产生较强的饱腹感,从而控制食欲。
据报道,澳大利亚研究发现,牛奶中的钙,在补充人体钙的同时还可以消耗脂肪,减少体内脂肪储存作用。奶中的乳清蛋白质和其他活性成分,也有助于增强人体消耗脂肪的能力。
另据报道,美国田纳西大学研究证实,牛奶中钙能帮助人体降低脂肪储备的同时加速脂肪燃烧速度。乳制品能帮助减肥的另一个重要原因是乳清蛋白,乳清蛋白所包含的营养成分可刺激肌肉组织构建,而这个过程也正是燃烧脂肪的过程。
4、抗癌:牛奶中含有一种CLA物质,能有效破坏人体内的致癌危险的自由基,并能迅速和细胞膜结合,使细胞处于防御致癌物质浸入的状态,从而起到防癌的作用。而牛奶中所含的钙能在人体肠道内有效破坏致癌物质,使其分解改变成非致癌物质,并排出体外。牛奶中的所含的维生素A、维生素B2、维生素D等对胃癌和结肠癌有一定的预防作用,而且牛奶中还含有多种能增强人体抗癌能力的免疫球蛋白抗体,也有防癌的作用。
另据报道,英国一份研究报告指出:牛奶中含有的维生素A、维生素C、钙等成分具有抗癌的作用。常喝牛奶可降低患口腔癌、结肠癌、膀胱癌、肺癌、乳腺癌、宫颈癌的危险性。
牛奶中的维生素A能使人体鳞状细胞癌及其他细胞癌消退,并刺激人体抗肿瘤的免疫系统;维生素C能抑制内源性亚硝胺的合成,并抑制致癌化合物对人体细胞的影响,钙能改善结肠黏膜的增殖,降低结肠癌的发生,因此,常喝牛奶可预防癌症。
5、增强免疫力:牛奶具有增强机体防病抗病能力,调节机体免疫功能,牛奶中的蛋白质是构成白血球和抗体的主要成分。实验证明,严重缺乏会使人的免疫细胞中的淋巴球大减,造成严重的免疫机能下降,易感染疾病。此外牛奶中的维生素和共轭亚油酸等有益成分具有一定的作用;而牛奶中的均衡的营养物质也可通过改善体质而提高免疫力。
6、美容:牛奶中含有丰富的蛋白质,乳脂肪、维生素、矿物质等成分容易被皮肤吸收,有防止皮肤干燥,可使皮肤表面死皮脱落,促进新细胞生长,防止皮肤老化,使皮肤光泽湿润、细腻,长期饮用还可以增加皮肤的活力和弹性,使皮肤变得清爽、润滑、洁白。研究证实,富含蛋白的食物具有益五脏、补虚损、强筋骨,滋润皮肤之功效。维生素、矿物质能使皮肤的代谢胜利进行,减少雀斑、黑斑、老年斑产生。油脂具有保水润肤的作用,故均衡的营养能滋养肌肤,抗皱。延缓皮肤衰老,防止皮肤老化。
(二)绿茶(Green tea),绿茶为茶科植物茶的叶子。性凉、味甘、苦。入心、肝、脾、肺、肾经。补益、清头目、除喝、消食、利尿通便、解毒、清热消火。现代医学研究绿茶能增强免疫力、延缓衰老、降血压、降血脂、降血糖、减肥、抗辐射、抗病毒、美容、抗癌等功效。
化学成分:蛋白质、氨基酸、茶多酚、咖啡因、茶色素、维生素、微量元素等成分。
药理作用:1、增强免疫力:绿茶浸液对细胞数及淋巴细胞绝对数的减少有明显的对抗作用。对外周α-醋酸茶酯(ANAE)阳性细胞百分率或绝对数在重度抑制组有显著的差异,并能保持由环磷酸酰胺(CY)引起的淋巴转反应抑制,给茶组SRBC(绵羊红细胞)溶血素抗体水平均高于给水组。因此,绿茶具有增强免疫力。
2、降血压:绿茶中的咖啡因、茶碱可直接兴奋心脏,扩张冠状血管,对末梢血管有直接扩张作用。绿茶浸提物中的没食子儿茶素,没食子酸酯0.1mg/kg静脉注射能使麻醉兔血压明显下降,并维持较长的时间,绿茶热水提取物中含锰的水溶出部分5mg/kg静脉注射时,仅使兔产生一过性的血压下降作用。
3、降血脂、防治动脉硬化:绿茶中的茶多酚能抑制在鹌鹑血清总胆固醇(TC)、甘油三酯(TG)及低密度脂蛋白(LDC-C)的升高有明显的抑制作用。其机理可能使通过抑制肠管组织对胆固醇的吸收,抑制体内胆固醇的合成,降低脂蛋白、脂肪酶的活性,促进肾上腺素诱致的脂肪酶活性,阻止食物中促胆固醇转化为胆酸的不饱和脂肪酸的氧化,从而促进脂质的分解和消除等途径来实现的。
4、利尿通便:茶的利尿功能主要是茶中的生物碱,特别是氨茶碱在起作用。茶碱一方面通过扩张肾微细血管促进尿液形成,另一方面刺激膀胱有利于尿的排出。茶的通便作用主要是茶多酚可增强大肠的收缩和蠕动作用来实现。
5、降血糖:研究表明,餐后喝茶能降低糖尿病人餐后血糖的峰值,这是由于茶能刺激胰岛素分泌,因而具有降血糖的作用。
据报道,英国科学家研究发现,茶对糖尿病极有好处。研究人员给16名志愿者喝含有75克葡萄糖溶液,糖液有4种配方,一组是白开水,二组是开水咖啡因,三组是1克茶包溶出的茶,四组是由3个茶包溶出的茶水,然后观察他们喝下糖水后150分钟内的血糖和胰岛素反应。结果发现,1克茶包就能让受试者在120分钟血糖更平稳,而对照组却没有变化。其机理使绿茶含有大量的茶多酚类物质的作用。
6、减肥:研究表明,绿茶含有多酚类儿茶素以及咖啡因,还含有多种维生素,既可解腻又可减肥。实验证实,肥胖者每天饮用3杯绿茶,一个月后血脂下降,体重减轻,正因如此,茶被世人称为“刮油茶”。
另据报道,德国科学家对动物实验证实,绿茶中的多酚化合物可以减少老鼠体内脂肪含量,从而起到了防止肥胖的作用。研究人员认为,茶多酚的减肥效果是通过减少营养在肠道内的吸收和加强脂肪氧化来达到的。
7、抗癌:现代医学研究认为,茶是一种防癌饮料。绿茶中抗癌有机物主要是茶多酚、茶碱和多种维生素以及无机盐等物质。我国预防医学科学家对140多种茶叶进行了实验,大量的实验数据都证明了茶对人体致癌性亚硝基化合物的形成有阻断作用,并能有效抑制癌基因与DNA共结合。实验报告特别指出,绿茶和乌龙茶防癌效果更好。
另据报道,台湾一项新的研究显示,不饮绿茶的吸烟者患肺癌的风险是那些每天至少喝一杯绿茶的人3倍之多。研究表明不喝绿茶的人,不论是吸烟者还是不吸烟者,与每日至少喝一杯绿茶的人相比,都有5.2倍的高发肺癌比率。该研究涉及170名肺癌患者和340健康对照者。
据台湾中心医科大学研究人员称,饮用绿茶和人体本身的基因型可能都影响肺癌。对不喝绿茶的人来说,基因看起来对癌症风险起了重要作用。报告还说,某特定类型的IGFI的绿茶饮用者与其他形式的IGFI的绿茶饮用者相比较肺癌的风险减少66%。此外,据日本报道,绿茶还可预防血癌。
8、防晒:据报道,美国一项研究表明,绿茶中儿茶素具有较强的抗氧化功能。将含有绿茶成分和护肤品涂抹在皮肤上,即使被强阳光照射,亦可让导致皮肤晒伤、松驰和粗糙的过氧化物减少约1/3。
美国阿拉巴马大学研究发现,阳光中的紫外线会刺激皮肤产生大量的氧化物,使人的皮肤变得粗糙、失去弹性。实验证明,涂抹儿茶素的人比涂抹安慰剂者皮肤中的过氧化物含量减少1/4-1/3。即皮肤受太阳光损伤的程度较轻微,从而证明,绿茶具有防晒功效,另一项研究显示,饮用绿茶其防晒效果与涂抹绿茶效果相同。
9、抗衰老:绿茶中茶多酚具有清除氧自由基的作用,其中咖啡因、儿茶素、表儿茶素有较强的抗氧化作用,可明显抑制次黄嘌呤和黄嘌呤氧化酶反应产生的含氧自由基引起IAR20肝细胞SCE的增高,其抑制作用比超氧化物歧化酶更强。
另据报道,日本研究发现,绿茶中的所含的鞣酸的抗老化功效是维生素E的18倍。抗衰老的机理是茶多酚能有效阻断人体自由基活性。儿茶素抗氧化,抗衰老。
10、防治心脏病:经常喝绿茶可预防心脏病。据报道,日本科学家研究发现,每天喝绿茶对心脏有益。因为绿茶中含有高水平的黄酮类化合物,它们可以通过抗氧化发挥作用。人体内的氧化过程主要是由于自由基蓄积导致细胞损伤造成的。氧化作用一直怀疑能够增加心脏病、中风和其它一些疾病发病的危险。多项研究已证实,摄入黄酮类化合物较多人。死于冠状动脉疾病的可能性降低。另外还有研究显示,摄入较多的黄酮类化合物能够降低心脏发病危险。
(三)共轭亚油酸(CLA),共轭亚油酸是存在于反刍动物牛、羊的乳脂及肉制品中一种天然的脂肪酸。是由脂肪酸——亚油酸衍生的共轭双键的多种位置和几何异物体的总称,即是亚油酸9,12——18:2的项生衍生物。它含有大约等量的C9,t11和t10,c12,两种异构体被证实具有很强的生理活性。据国外大量的研究证实,共轭亚油酸具有多种生物学功能:减肥、降血脂、防治糖尿病、抗癌,增强免疫功能,抗氧化等功效。
生理功能:1、减肥:研究表明,共轭亚油酸具有减少脂质沉积和增加脂肪细胞中的脂肪酸的氧化与分解,有“脂肪燃烧剂”之称。经国内外科研机构大量的试验证明,共轭亚油酸能显著降低大鼠体内的脂肪含量,没有任何毒副作用。经40多名肥胖和超重为期2个月的试食,试食者的体重和体脂肪明显降低,特别是腰围、臀以及三角肌,肩胛等处的皮下脂肪减少尤为明显,试食者普遍感到精神旺盛、睡眠好、有高血压的试食者血压降低到正常范围。据专家介绍,共轭亚油酸可能是通过5个方面的起到减少体脂肪的作用。(1)、减少饮食后脂肪在人体内的吸收贮存。(2)、加快脂肪细胞分解速度和在线粒体中的脂肪燃烧速度。(3)、减少脂肪分裂和抑制前脂肪细胞3t3——L1的增殖与分化。(4)、减少总的脂肪分裂细胞。(5)、降低炎症细胞因子的释放,抑制慢性炎性疾病的抵抗力。共轭亚油酸还可减少肌肉蛋白的释放,增进胰岛素调控葡萄糖转化为能量,从而起到减肥瘦身的功效。
国外学者研究证明,共轭亚油酸具有重新分配身体组成的能力。喂食共轭亚油酸的猪相比于喂葵花籽油猪皮下脂肪少,而肌肉组织更多,这表明,共轭亚油酸具有调节脂肪和肌肉组织重新分配的功能。大量的实验结果表明,共轭亚油酸可以减少脂肪的积累。也有国外学者对大鼠补充了共轭亚油酸35天后,腹膜及子宫脂肪垫的重量,减少了13——32%,体重减少15——29%,小鼠补充共轭亚油酸后,脂肪降低了57——60%,特别是腹部脂肪降低最为明显,而身体的肌肉质量增加了5——14%,证明喂食了共轭亚油酸可以抑制含有脂肪的油脂吸收。另据国外有关报道,异构化亚油酸对控制人体体重及减肥有独特的作用,它对脂肪细胞有直接作用,能防止脂肪从食物中吸收脂肪,抑制脂肪细胞生长,促进脂肪燃烧代谢。肥胖者每天摄入共轭油酸,即在不减少热量摄入,也不运动的情况下仍扔有减肥的效果。国外还有人体试验结果表明,平均体重为156磅的健康人,每天服3.6克共轭亚油酸,三个月后体内脂肪降低20%,因此共轭亚油酸的减肥效果受到国际社会的关注。
2、降血脂:共轭亚油酸能降低血清中的低密度脂蛋白胆固醇浓度和甘油三酯浓度,阻止脂肪和血小板在动脉壁沉积。研究发现,共轭亚油酸通过结合和活化过氧化物酶增生固子激活受体α(PPARα)来调节脂质代谢,降低血浆中低密度脂蛋白、甘油三酯和总胆醇浓度,从而抑制动脉硬化的发生,具有降血脂作用。
3、防治糖尿病:适当浓度共轭亚油酸可明显降低体内葡萄糖,胰岛素和甘油三酯水平。在饲喂含有共轭亚油酸5%的高糖饲料大鼠的葡萄糖耐量试验,血糖反应正常。另据报道,共轭亚油酸能提高肝细胞中胰岛素受体的敏感性,使受损的葡萄糖耐受量恢复正常,对糖尿病具有一定的防治作用。
4、抗癌:共轭亚油酸具有抑制肿癌细胞生长,减少正常细胞的癌变生理作用和癌症转移。它还能显著降低胃癌、前列腺癌、乳腺癌、皮肤癌等多种癌症的发病率。其抗癌作用包括:(1)抑制化学致癌剂与DNA附加体的形成;(2)、抑制细胞素LTB4及内毒素等的产生;(3)增强免疫力;(4)抑制持有激素受体的癌细胞增殖。另有报道,大量的动物模型和人体癌细胞体外培养模型实验发现,共轭亚油酸在发展的各阶段均有抑制作用。其抑制癌症包括开始阶段、发展和转移阶段,甚至是癌症的发展全过程。及乌氨酸脱羧酶和蛋激酶C等酶的活性,以及抑制癌细胞蛋白质和核酸的形成。
5、美容养颜:研究表明,共轭亚油酸酯具有优异的亲脂性,能防止皮肤细胞脂质过氧化及紫外线引起的自由基损伤,具有防止皮肤干燥,粗糙和色素斑的等作用。国外已经将共轭亚油酸酯应用到美容养颜的化妆品领域。
6、增强免疫功能:研究表明:共轭亚油酸参与免疫系统的调节作用,促进淋巴细胞增生和巨噬细胞杀伤力,促进脾脏和血清免疫球蛋白IgG、IgM、IgA的增强,还能降低免疫造成骨骼肌的异化,同时又不是免疫效益减弱,延缓肌体免疫能力衰退。动物实验表明,共轭亚油酸能增强大鼠的植物血球凝集素反应和巨噬细胞的噬菌作用。另有报道,共轭亚油酸能促进大鼠脾脏淋巴细胞增殖及白细胞介质的(IL-2)和抗体的合成;使大鼠血清的IgG和IgM浓度上升。
7、促进骨骼发育和生长:研究显示,共轭亚油酸能增加骨骼的合成速度,降低PGE2的合成,正向调节胰岛素生长因子,以促进骨骼的形成与生长。另有报道,在胫骨和大腿骨细胞培养系统中添加共轭亚油酸其PGE2产生明显下降。有人通过小鼠实验证实,共轭亚油酸能够促进骨组织的分裂与再生,促进软骨组织细胞合成和矿物质在骨组织中的沉积。国外学者研究发现,共轭亚油酸能增加小鼠骨形成速度,对骨骼的生长具一定的作用。共轭亚油酸调节骨质形成的机理可能是因为共轭亚油酸引起PGE2浓度变化,而PGE2浓度过高会抑制骨质的形成,因为共轭亚油酸能够有效降低PGE2的浓度,因此,可以促进骨的形成与生长。
(四)丙酮酸钙(Caleiun Pyruvate),丙酮酸钙是丙酮酸和矿物质钙的化合物。丙酮酸是存在于天然蔬菜和水果中,而钙是人体不可缺少的一种矿物质。它们是人体代谢中最重要的中间物质之一,对人体健康十分重要。据国外大量的研究证实,丙酮酸钙具有减肥、美容养颜、增强运动耐力、保护心血管、清除自由基、降低胆固醇、防癌抗癌、延缓衰老等功能。
生理功能:1、减肥:丙酮酸钙能促进脂肪燃烧,加速脂肪消耗与代谢,具有减轻体重的作用。研究表明,丙酮酸钙是位于脂肪细胞中心代谢途径上最关键的中间代谢产物,能联系糖酵解途径和三羧酸循环,直接调节人体脂质和能量代谢,起燃烧与分解脂肪的作用,具有明显的减肥效果。而且减肥不减蛋白质含量,减肥后不反弹,减肥剂量范围广,对人体无残留等。据报道,美国匹兹堡大学研究中心经过27年的研究和临床应用发现,丙酮酸钙能将脂肪转化能量,有助于提高脂肪降解,脂肪降解率可达48%。并可使机体内的蛋白质降解控制在最小程度。
2、降低胆固醇:研究发现,造成心脑血管疾病的主要因素是血液中LDL-胆固醇的含量增加,丙酮酸钙离子可与LDL-胆固醇作用,促进其分解,在医学上有十分重要的意义,能有效预防高血脂,肥胖及相关疾病的发生。
3、改善心脏功能:研究认为,丙酮酸钙作为心肌细胞线粒体,及时供给心肌活动所需能量提高心肌泵血耐力,从而改善心功能。
4、美容:研究发现,丙酮酸钙吸收性好,可以经同皮肤透皮吸收,表皮、肠胃都有很好的吸收,现已在某些美容院已有使用丙酮酸钙溶液做美容护肤,对老化皮肤部位使用丙酮酸的为主的养肤液,经过一定的时间处理后,衰老的皮会自动脱落,新皮在2-5天会自动生成。
(五)L——肉碱(Carmitne),又名肉毒碱,维生素BT。是存在于牛羊肉、脾脏、人乳等中的天然活性成份。由于肉碱具有多种营养和生理功能,已被视为人体的必需营养素。L——肉碱能参与蛋白质的合成,也不是正真意义上的维生素,只是一种类似维生素的物质。营养等研究证实有减肥、降低胆固醇、防治脂肪肝、抗疲劳、改善糖尿病、延缓衰老等功能。
生理功能:1、减肥:肉碱的生理作用是促进人体脂肪燃烧转化为能量而被消耗。它的主要作用是作为载体以脂酰形式参与脂肪的燃烧与代谢,在线粒体膜上的肉碱,在脂酰转移酶Ⅰ、Ⅱ及转位酶的作用下,将长链脂肪从线粒体模外运入线粒体模内,使脂肪燃烧代谢,提高体内脂肪的燃烧率,促进使其进行氧化,并转变为能量,从而减少脂肪的积累,以达到减肥的目的。另有报道,肉碱是脂肪代谢必不可缺少的物质,其最重要的功能是促进脂肪燃烧与代谢,提高体内脂肪的燃烧率,具有良好的减肥瘦身效果。有人用高脂饲料诱导建立肥胖模型(平均体增加1.5倍),喂食肉碱125mg/kg、BW、250mg/kg、BW、500mg/kg、BW,6周后测定体重。睾丸及肾脂肪垫质量,胰岛素(LNS)及瘦素水平,结果显示,肉碱具有明显的抑制大鼠肥胖的作用。
2、降低胆固醇:研究表明,肉碱具有降低血液中甘油三酯和胆固醇的作用,具有抑制大鼠肥胖的作用。
3、防治脂肪肝:饮酒会促进肝脂肪合成,造成脂肪在肝脏中积蓄形成脂肪肝,肉碱能燃烧分解脂肪,抑制脂肪在肝脏中的积聚,而防治脂肪肝。
4、抗疲劳:研究表明,肉碱是通过体内脂肪燃烧并转化为能量,来提高运动员的爆发力和长时间运动持久耐力,提高基础代谢,改善心肌营养状况,提高运动体能,减少运动引起的组织损伤,加快返回最佳运动状态的速度。正是由于补充肉碱有利于强烈运动后的恢复和增强体能,国外运动员从上世纪80年代就开始在训练和比赛期间补充肉碱。例如马拉松运动员在6星期内每天补充2克肉碱,能使跑速平均增加5.7%,因此,补充肉碱可提高运动成绩,抗疲劳。
(六)α-硫辛酸(α-Lipoic acid),α-硫辛酸是存在于人体内一种天然的有些类似维生素的抗氧化剂。在人体内存在细胞微粒体内,与特殊的酶蛋白的赖氨酸残基和氨基结合成硫辛酸胺(即硫辛酰赖氧酸)。α-硫辛酸属于B族化合物,是一种强抗氧化剂,其分子具有双亲性,因而自由的来往于细胞内外。经国内外大量的研究具有抗氧化、减肥、防治糖尿病、抗炎、增强免疫力、防治白内障、保肝等功能。
生理功能:α-硫辛酸在各种组织中(包括脑组织)中易于被细胞所吸收和转变,并在二氢硫辛酸脱氢酶等作用下还原成二氢硫辛酸,二氢硫辛酸也可以从细胞转移,并在细胞外提供抗氧化作用。研究表明,α-硫辛酸和二氢硫辛酸除单态氧之外,对次氯酸,过氧化自由基,超氧阴离子均有一定的清除能力。二氢硫辛酸还能使其他抗氧化剂从氧化态或自由基形成得到还原,从而获得再生,包括谷胱甘肽,辅酶Q10、维生素C的直接还原和维生素E的间接还原,从而使体内的主要抗氧化物得以发挥作用,从而抑制脂肪过氧化作用。另据有关报道,α-硫辛酸能直接清除人体内的活性氧和快速清除自由基,及时保护机体免疫被自由基的损害,延缓了衰老过程。
2、减肥:α-硫辛酸是胰岛素信号传递系统中的一部分,它可使3T3-L1前脂肪细胞分化,抑制中性细胞的积聚。据研究,α-硫辛酸可使大鼠摄食量减少,增加热量消耗,从而达到减肥的作用,据国内报道,α-硫辛酸和乙酰肉碱搭配能大幅度增加脂肪酸的分解,预防多种肥胖相关的疾病。
据介绍,乙酰肉碱负责将脂肪细胞内的脂肪酸从细胞浆转移到线粒体内,使得脂肪酸被线粒体代谢,转化为能量,如果撮入脂肪超过线粒体的代谢能力,多余脂肪就会在血管、肝脏等部位沉积,导致动脉硬化、脂肪肝等疾病。研究发现,α-硫辛酸是一种天然抗氧化剂,能保护氧化受损的线粒体,也能促进脂肪细胞中线粒体增生,从而增强对脂肪的分解代谢。研究人员对3T3-L1脂肪细胞实验证实,联用α-硫辛酸与乙酰肉碱可以显著增加线粒体基质、线粒体DNA表达、线粒体的氧气消耗和3T3-L1脂肪细胞内的脂肪酸氧化,单用乙酰肉碱或α-硫辛酸对线粒体的功能和生物合成没有显著影响。另据报道,α-硫辛酸它具有酶的作用,可阻断新葡萄糖转化为脂肪,因此可以达到减肥瘦身的目的。
3、降血糖:II型糖尿病发病的最重要因素是由胰岛素的抵抗性是胰岛素应答能力下降,葡萄糖无法氧化而造成血糖升高。α-硫辛酸能使胰岛素应答能力恢复,使胰岛素刺激细胞激发葡萄糖氧化并合成肝糖原,使糖代谢恢复正常,从而降低血糖值。研究报道,给大鼠100毫克硫辛酸对II型糖尿病的葡萄糖处理能可提高50%。另有报道,每天给予α-硫辛酸50毫克10天,可使胰岛素刺激葡萄糖处置能力提高30%。据美国加州大学科研人员研究发现,α-硫辛酸可辅助治疗II型糖尿病,改善胰岛素功能与葡萄糖代谢。α-硫辛酸还可使葡萄糖的燃烧利用增加,从而降低血糖,同时还能改善糖尿病患者的血糖控制,使患者减少使用胰岛素和降糖药。
α-硫辛酸可保护神经细胞,糖尿病的一大并发症就是神经组织病变。而α-硫辛酸可使糖尿病患者的神经病变明显减轻,对尚未出现神经病变的糖尿病患者有预防和保护作用。
4、保护肝脏:据报道,美国科学家曾对3名食用毒蘑菇造成的肝坏死患者采用α-硫辛酸治疗,结果3名患者的病情在短时间得到控制,肝功能恢复正常。另外α-硫辛酸还可结合分解肝内毒素,减轻肝炎症状,恢复肝功能。
5、美容养颜:α-硫辛酸具有很强的抗氧化作用,能抑制黑色素的生成酶的活性和紫外线晒伤的功能,它能防止皮肤老化和色素沉着,减少皮肤黑色素的形成。动物实验,α-硫辛酸能抑制酪氨酸酶的活性,抑制黑色素的产生,减少黑色素在面部沉积。另外α-硫辛酸还能防紫外线对皮肤的伤害,防止晒斑和色素班的生成。
α-硫辛酸是维生素类药物,在体内作为丙酮酸脱氢酶的辅助因子,具有很强的抗氧化作用,能清除自由基,螯合铜离子的功能,提高谷胱甘肽转移酶的活性,从而生成的大量还原型谷胱甘肽。还原型谷胱甘肽的巯基能与酪氨酸酶的铜离子结合而抑制酪氨酸酶活性,减少黑色素的生成,α-硫辛酸还可通过抑制眼畸形相关转录因子(M1TF),从而抑制酪氨酸酶,减少黑色素的生成。
此外,α-硫辛酸还能防治心血管病、中风、老年性疾呆症、延缓衰老等功效。
(七)菊粉(inulin)又称菊糖,是从天然植物菊芋中提取的果聚糖化合物。是目前发现的最好的水溶性膳食纤维之一。菊粉为体内双歧杆菌增长因子,也是一种重要的脂肪替代品,热量低,溶解性好,为白色无定形粉末,相对分子量6000。
主要成分:菊粉含β-1,2-糖键连接的聚合果糖,聚合度为30-60混合物,平均聚合度为10,含少量单糖、双糖。
生理功能:1、改善肠道环境、促进益菌增殖:菊粉在消化道上端不能被消化,以完整的形式到达大肠被双歧杆菌利用,促进大肠的双歧杆菌、乳酸杆菌等生长、发酵产生的SCFA使大肠内PH值下降,从而抑制大肠内一些不耐酸的病源微生物如沙门氏菌等腐败菌的生长改善肠道环境,减少肠道内腐败物质的产生。
2、防治便秘:菊粉是水溶性膳食纤维,能使大肠蠕动,有利于大肠内容物向大肠运动,增加排便次数,有利粪便排出。同时菊粉具有很强的吸水性,增加大便中的含水量,由此导致大便变软,重量增加,排便因而变得轻松。
3、降血脂:一些研究数据显示,菊粉可以降低血清总胆固醇(TC)和低度脂蛋白胆固醇(LDC-C),改善血脂状况。其原因,一方面是因为菊粉作用为膳食纤维可吸收肠内脂肪,形成脂肪-纤维复合物随粪便排出,有助于血脂水平的降低。另一方面,菊粉发酵终产物主要为短链脂肪酸SCFA(乙酸、丙酸、丁酸)和有机酸(乳酸、琥珀酸、丙酮酸等),其中丙酸可以抑制胆固醇的合成,同时增加胆汁分泌量;乳酸盐调节肝脏代谢,从而降低血脂水平。
4、降血糖:经过大量的研究发现,糖尿病人摄入高纤维的食品后不但不会加重餐后高血糖,而且还可以改善患者的葡萄糖耐量和对胰岛素的敏感性,因此具有降血糖作用。菊粉系果糖聚合物,是非常好的水溶性膳食纤维,能延缓碳水化合物的消化吸收;故可以减轻餐后高血糖。另外还可以使胰岛素依赖型患者的胰岛素需要量减少30%-40%,非胰岛素依赖型患者的胰岛素需要量减少75%-100%。并可以使患者血压下降,抑制患者的体重增加。
5、减肥:研究表明,菊粉是可溶性膳食纤维,在口腔、胃和小肠内不能被消化吸收,只能被肠道某些细菌完全发酵,是低热量食品。能在胃中吸水膨胀,形成黏膜胶体,使人易产生饱腹感并能延长胃的排空时间,从而减少食物的摄入量,减少食物在小肠的时间,还能在小肠与蛋白质,脂肪等物质形成复合物,不利于这些营养的吸收,因此达到减肥的目的。另外菊粉还能吸收胆汁酸,降低胆固醇的合成吸收,不能经由糖-脂代谢途径合成脂肪,所以来减肥。
6、增强免疫力:菊粉通过对双歧杆菌的增殖作用,能产生大量的免疫性物质,如S-TGA免疫球蛋白,它在肠壁的附着力明显大于其他免疫球蛋白。菊粉还能显著提高抗体细胞的数目和NK细胞活性。此外,有益菌代谢产物的增多和有害菌的减少,有益机体细胞免疫和体液免疫增强。
7、促进矿物质的吸收:菊粉能提高人体对钙、镁等矿物质的吸收。可提高骨密度,防治骨质疏松。
8、抗龋齿:龋齿是由变异链球菌将糖生成水不溶性葡聚糖而引起的。菊粉不能被变异链球菌等利用作为营养源,该菌产生的葡萄糖转移酶不能将葡萄糖生成不溶性和黏着性的葡聚糖,口腔产酸菌发酵菊粉生成乳酸,也远远低于发醇蔗糖所产生的酸。菊粉也不易使龋齿病源菌凝集,其齿面上生成的乳酸量比蔗糖低50%左右。
综上所述,本产品具有提高免疫力、减肥、降血压、降血脂、降血糖、美容等功能。
六、制作工艺:1、调配混合:将配方中的所有原料按物理特性进行混合。
2、搅拌:将混合好的原料充分搅拌均匀。
3、检验包装:将搅拌均匀的原料,检验合格包装成为正式产品。
调配混合是将配方中的原料按物理特性进行混合工序。搅拌是将混合好的原料充分搅拌均匀的工序。检验包装是将搅拌均匀的原料检验合格包装成为正式产品。
七、质量标准:
1、理化指标:
2、服用方法:每日50-100克。
3、适用人群:男女老幼、儿童、青少年人群。
八、具体实施方式:
实施例:取牛奶40千克,绿茶10千克,共轭亚油酸7.5千克,丙酮酸钙6千克,L-肉碱4千克,α-硫辛酸2千克,维生素10克,菊粉2.5千克,辅料混合,并充分搅拌均匀检验合格,包装成为正式产品。
Claims (2)
1.瘦身美奶茶的制作工艺为:调配混合、搅拌、检验、包装成为正式产品,
2.工艺条件:牛奶40千克,绿茶10千克,共轭亚油酸7.5千克,丙酮酸钙6千克,L-肉碱4千克,α-硫辛酸2千克,维生素10克,菊粉2.5千克,辅料混合,并充分搅拌均匀,检验合格,包装成为正式产品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100492163A CN102090453A (zh) | 2011-02-21 | 2011-02-21 | 瘦身美奶茶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100492163A CN102090453A (zh) | 2011-02-21 | 2011-02-21 | 瘦身美奶茶 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102090453A true CN102090453A (zh) | 2011-06-15 |
Family
ID=44123848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100492163A Pending CN102090453A (zh) | 2011-02-21 | 2011-02-21 | 瘦身美奶茶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102090453A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104721208A (zh) * | 2015-02-02 | 2015-06-24 | 山东省中医药研究院 | 一种预防和治疗脂肪肝及降血脂的药物制剂 |
ITUA20162588A1 (it) * | 2016-04-14 | 2017-10-14 | Difass Int S R L | Uso di una composizione comprendente acido alfa-lipoico. |
CN109699744A (zh) * | 2018-12-27 | 2019-05-03 | 光明乳业股份有限公司 | 一种辅助降血糖乳粉及其制备方法 |
CN110403014A (zh) * | 2019-07-24 | 2019-11-05 | 海普诺凯营养品有限公司 | 一种能抑制食欲的营养粉及其制备方法与应用 |
CN111357821A (zh) * | 2020-04-01 | 2020-07-03 | 北京若尧健康科技有限公司 | 一种美容养颜瘦身组合物及其制备方法 |
-
2011
- 2011-02-21 CN CN2011100492163A patent/CN102090453A/zh active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104721208A (zh) * | 2015-02-02 | 2015-06-24 | 山东省中医药研究院 | 一种预防和治疗脂肪肝及降血脂的药物制剂 |
CN104721208B (zh) * | 2015-02-02 | 2019-01-18 | 山东省中医药研究院 | 一种预防和治疗脂肪肝及降血脂的药物制剂 |
ITUA20162588A1 (it) * | 2016-04-14 | 2017-10-14 | Difass Int S R L | Uso di una composizione comprendente acido alfa-lipoico. |
CN109699744A (zh) * | 2018-12-27 | 2019-05-03 | 光明乳业股份有限公司 | 一种辅助降血糖乳粉及其制备方法 |
CN110403014A (zh) * | 2019-07-24 | 2019-11-05 | 海普诺凯营养品有限公司 | 一种能抑制食欲的营养粉及其制备方法与应用 |
CN111357821A (zh) * | 2020-04-01 | 2020-07-03 | 北京若尧健康科技有限公司 | 一种美容养颜瘦身组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5985138B2 (ja) | エネルギー消費促進剤 | |
JP6684966B2 (ja) | 新規なラクトバチルス・サケイ及びそれを含む組成物 | |
WO2005023021A1 (ja) | ダイエット食品 | |
CN111084381A (zh) | 生酮营养代餐粉及应用 | |
CN101579120A (zh) | 一种具有减肥功能的营养食品及其制备方法 | |
US20200171115A1 (en) | Composition for preventing or treating visceral fat obesity containing extract of salvia miltiorrhiza radix | |
KR20120097516A (ko) | 고지혈증 개선제 및 빈혈 개선 조성물, 요산치 저하 조성물 및 음식품 | |
CN108719984B (zh) | 一种针对痛风人群的代餐营养棒及其制备方法 | |
CN105815514A (zh) | 藜麦减肥奶茶 | |
CN106107463A (zh) | 超级藜麦抗疲劳奶茶制作工艺 | |
CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
CN103190483A (zh) | 儿童成长奶茶 | |
CN102090453A (zh) | 瘦身美奶茶 | |
KR19990035872A (ko) | 체지방률을 낮추고 체조성을 개선시키는 식품 조성물 및 체지방률을 낮추고 체조성을 개선시키는 방법 | |
CN101791079A (zh) | 减肥美容胶囊 | |
RU2491083C2 (ru) | Применение фитоэкдизонов и получение композиции для воздействия на метаболический синдром | |
CN105707378A (zh) | 黑青稞瘦身咖啡 | |
CN104757535A (zh) | 黑枸杞减肥片(茶) | |
CN103330118A (zh) | 减肥药物 | |
CN109170916A (zh) | 一种强身健体食品组合物及其制备方法 | |
CN113349377A (zh) | 一种瘦身益生菌软胶囊及其制备方法 | |
CN112603953A (zh) | 一种减肥降脂外用组合物及其制备方法 | |
CN109303115A (zh) | 生酮减肥代餐奶昔 | |
CN103037854A (zh) | 潘多汀派生物或提琴形凹唇姜萃取物的促进增加肌肉、抗疲劳及提高运动执行能力相关新用途 | |
CN103181557A (zh) | 具有减肥功能的营养食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110615 |